mail2

Spectrum Library

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and … – PubMed – NCBI

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and … – PubMed – NCBI.

See comment in PubMed Commons below

Mult Scler. 2014 Oct 24. pii: 1352458514555785. [Epub ahead of print]

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.

Author information

  • 1Center of Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain/Institute of Neurology, Medical University of Vienna, Austria/These authors contributed equally to this work.
  • 2Center of Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain/These authors contributed equally to this work.
  • 3Center of Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • 4Center of Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain/Department of Pediatrics I, Division of Pediatric Neurology, Innsbruck Medical University, Innsbruck, Austria/Pediatric Neurology, Witten/Herdecke University, Children’s Hospital Datteln, Germany.
  • 5Servicio de Neurología, Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain.
  • 6Hospital Universitario Donostia, San Sebastián, Spain.
  • 7Hospital Universitari Dr. Josep Trueta, IDIBGI, Girona, Spain.
  • 8Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • 9Departament of Neurology, University Hospital “12 de Octubre”, Centro de Investigación Biomédica en red sobre Enfermedades Neurodegenerativas (CIBERNED), Departamento de Medicina, Complutense University, Madrid, Spain.
  • 10Hospital Universitari La Fe de Valencia, Valencia, Spain.
  • 11Servei de Neurologia-Neuroimunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • 12Center of Neuroimmunology, Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain/Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  • 13Service of Neurology, Hospital Clínic. Villarroel 170, 08036 Barcelona, Spain asaiz@clinic.ub.es.

Abstract

OBJECTIVE:

We aimed to report the frequency and implications of antibodies to myelin oligodendrocyte glycoprotein (MOG-ab) in adults with demyelinating syndromes suspicious for neuromyelitis optica (NMO).

METHODS:

Samples from 174 patients (48 NMO, 84 longitudinally extensive myelitis (LETM), 39 optic neuritis (ON), and three acute disseminated encephalomyelitis (ADEM) who presented initially with isolated LETM) were retrospectively examined for AQP4-ab and MOG-ab using cell-based assays.

RESULTS:

MOG-ab were found in 17 (9.8%) patients, AQP4-ab in 59 (34%), and both antibodies in two (1.1%). Among the 17 patients with MOG-ab alone, seven (41%) had ON, five (29%) LETM, four (24%) NMO, and one (6%) ADEM. Compared with patients with AQP4-ab, those with MOG-ab were significantly younger (median: 27 vs. 40.5 years), without female predominance (53% vs. 90%), and the clinical course was more frequently monophasic (41% vs. 7%) with a benign outcome (median Expanded Disability Status Scale: 1.5 vs. 4.0). In eight patients with paired serum-cerebrospinal fluid (CSF) samples, five had MOG-ab in both samples and three only in serum. Antibody titres did not differ among clinical phenotypes or disease course. MOG-ab remained detectable in 12/14 patients (median follow-up: 23 months) without correlation between titres’ evolution and outcome.

CONCLUSION:

MOG-ab identify a subgroup of adult patients with NMO, LETM and ON that have better outcome than those associated with AQP4-ab. MOG-ab are more frequently detected in serum than CSF and the follow-up of titres does not correlate with outcome.

© The Author(s), 2014.